MX2008011319A - Uso de inhibidores de cinasa jun n-terminal para tratar glaucoma. - Google Patents

Uso de inhibidores de cinasa jun n-terminal para tratar glaucoma.

Info

Publication number
MX2008011319A
MX2008011319A MX2008011319A MX2008011319A MX2008011319A MX 2008011319 A MX2008011319 A MX 2008011319A MX 2008011319 A MX2008011319 A MX 2008011319A MX 2008011319 A MX2008011319 A MX 2008011319A MX 2008011319 A MX2008011319 A MX 2008011319A
Authority
MX
Mexico
Prior art keywords
jun
inhibitors
terminal kinases
treat glaucoma
compositions
Prior art date
Application number
MX2008011319A
Other languages
English (en)
Spanish (es)
Inventor
Debra L Fleenor
Iok-Hou Pang
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MX2008011319A publication Critical patent/MX2008011319A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2008011319A 2006-03-31 2007-03-14 Uso de inhibidores de cinasa jun n-terminal para tratar glaucoma. MX2008011319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/394,893 US7803824B2 (en) 2004-10-29 2006-03-31 Use of inhibitors of Jun N-terminal kinases to treat glaucoma
PCT/US2007/063961 WO2007117849A2 (en) 2006-03-31 2007-03-14 Use of inhibitors of jun n-terminal kinases to treat glaucoma

Publications (1)

Publication Number Publication Date
MX2008011319A true MX2008011319A (es) 2008-09-19

Family

ID=38523463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011319A MX2008011319A (es) 2006-03-31 2007-03-14 Uso de inhibidores de cinasa jun n-terminal para tratar glaucoma.

Country Status (13)

Country Link
US (3) US7803824B2 (enExample)
EP (1) EP2004158A2 (enExample)
JP (1) JP5241033B2 (enExample)
KR (1) KR20080108503A (enExample)
CN (1) CN101415407B (enExample)
AR (1) AR060222A1 (enExample)
AU (1) AU2007235111B2 (enExample)
BR (1) BRPI0710099A2 (enExample)
CA (1) CA2644721A1 (enExample)
MX (1) MX2008011319A (enExample)
TW (1) TWI419694B (enExample)
WO (1) WO2007117849A2 (enExample)
ZA (1) ZA200807667B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
WO2010151638A1 (en) * 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
AU2014301631A1 (en) * 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
AU2015281361A1 (en) * 2014-06-26 2016-11-17 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040847A1 (en) * 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
KR20010083884A (ko) 1998-10-13 2001-09-03 세파론, 인코포레이티드 눈 질환 치료제
ATE253062T1 (de) 1998-12-17 2003-11-15 Hoffmann La Roche 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
EP1175399B1 (en) 1999-04-23 2009-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
CN1304375C (zh) 1999-08-19 2007-03-14 信号药品公司 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1289523A1 (en) 2000-06-01 2003-03-12 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
CA2437248A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
WO2003018020A1 (en) 2001-08-23 2003-03-06 Takeda Chemical Industries, Ltd. Jnk inhibitors
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
JP2003129190A (ja) 2001-10-19 2003-05-08 Sumitomo Metal Ind Ltd マルテンサイト系ステンレス鋼およびその製造方法
US20030138819A1 (en) 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
ATE465153T1 (de) * 2002-02-28 2010-05-15 Eisai R&D Man Co Ltd Neue indazolverbindungen mit kondensiertem ring
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
US7465736B2 (en) 2002-06-14 2008-12-16 Laboratoires Serono S.A. Azole methylidene cyanide derivatives and their use as protein kinase modulators
CA2497977A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040092568A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Also Published As

Publication number Publication date
BRPI0710099A2 (pt) 2011-08-02
US20120004274A1 (en) 2012-01-05
US20100311716A1 (en) 2010-12-09
TWI419694B (zh) 2013-12-21
ZA200807667B (en) 2010-07-28
EP2004158A2 (en) 2008-12-24
WO2007117849A2 (en) 2007-10-18
TW200744601A (en) 2007-12-16
KR20080108503A (ko) 2008-12-15
AR060222A1 (es) 2008-06-04
AU2007235111A1 (en) 2007-10-18
JP2009532373A (ja) 2009-09-10
AU2007235111B2 (en) 2012-03-22
US20060172991A1 (en) 2006-08-03
CN101415407A (zh) 2009-04-22
JP5241033B2 (ja) 2013-07-17
CA2644721A1 (en) 2007-10-18
CN101415407B (zh) 2011-05-11
US7803824B2 (en) 2010-09-28
WO2007117849A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
TW200744601A (en) Use of inhibitors of Jun N-terminal kinases to treat glaucoma
MX2009002377A (es) Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
NO20084435L (no) C-MET proteinkinaseinhibitorer
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
MX2009006690A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
ZA200906264B (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
CA2641347C (en) Indazole-heteroaryl derivatives
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration